Dr David House (GlaxoSmithKline)

Covalent fragment screening in cell-based phenotypic models of disease: a collaborative approach

22 June 2021 | By Dr Andrew Powell (GlaxoSmithKline), Dr David House (GlaxoSmithKline), Dr Jacob Bush (GlaxoSmithKline), Dr Katrin Rittinger (The Francis Crick Institute), Dr Simon Boulton (The Francis Crick Institute)

The application of chemical perturbation approaches in phenotypic models is often used to identify protein targets for therapeutic discovery. Increasingly, small molecule fragments which covalently bind to their protein targets are being used to explore the druggable proteome and the resulting fragment‑protein interactions are characterised by chemoproteomic techniques. In this…